

# Fibroblast Growth Factor Receptor 4 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/F3A00A9CA682EN.html>

Date: January 2020

Pages: 144

Price: US\$ 3,500.00 (Single User License)

ID: F3A00A9CA682EN

## Abstracts

Fibroblast Growth Factor Receptor 4 - Pipeline Review, H1 2020

### SUMMARY

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) pipeline Target constitutes close to 23 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The latest report Fibroblast Growth Factor Receptor 4 - Pipeline Review, H1 2020, outlays comprehensive information on the Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. It is required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. It phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 5, 5, 1, 1 and 3 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Metabolic Disorders, Central Nervous System and Musculoskeletal Disorders which include indications Hepatocellular Carcinoma, Bile

Duct Cancer (Cholangiocarcinoma), Solid Tumor, Breast Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Lung Adenocarcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Ovarian Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Type 2 Diabetes, Adenoid Cystic Carcinoma (ACC), Bladder Cancer, Esophageal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Liver Cancer, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Non-Alcoholic Steatohepatitis (NASH), Obesity, Prostate Cancer, Squamous Non-Small Cell Lung Cancer, Thyroid Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Achondroplasia, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Colorectal Cancer, Constipation, Endometrial Cancer, Epithelial Ovarian Cancer, Ewing Sarcoma, Fallopian Tube Cancer, Gallbladder Cancer, Gastrointestinal Tract Cancer, Head And Neck Cancer, High-Grade Glioma, Liver Cirrhosis, Lymphoma, Melanoma, Metastatic Bile Duct Cancer, Metastatic Biliary Tract Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Nasopharyngeal Cancer, Non-Small Cell Lung Cancer, Oral Mucositis, Osteosarcoma, Peritoneal Cancer, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Primary Sclerosing Cholangitis, Primitive Neuroectodermal Tumor (PNET), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Rhabdomyosarcoma, Salivary Gland Cancer, Small-Cell Lung Cancer, Spinal Cord Injury, Squamous Cell Carcinoma, Thymic Carcinoma and Triple-Negative Breast Cancer (TNBC).

Furthermore, this report also reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)

The report reviews Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or

EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Overview

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Companies

Involved in Therapeutics Development

Abbisko Therapeutics Co Ltd

Akero Therapeutics Inc

ArQule Inc

Bayer AG

Blueprint Medicines Corp

Eddingpharm Inc

Eisai Co Ltd

Eli Lilly and Co

EUSOL Biotech Co Ltd

Everest Medicines Ltd

Genosco Inc

H3 Biomedicine Inc

ImmunoForge Co Ltd

Incyte Corp

InnoCare Pharma Ltd

Johnson & Johnson

NGM Biopharmaceuticals Inc

Principia Biopharma Inc

QED Therapeutics Inc

Vichem Chemie Research Ltd

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Drug Profiles

ABSK-011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AKR-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

derazantinib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Dormant Products

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Discontinued Products

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Product Development Milestones

Featured News & Press Releases

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indications, H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Products under Development by Companies, H1 2020 (Contd..7), H1 2020

Products under Development by Companies, H1 2020 (Contd..8), H1 2020

Number of Products under Investigation by Universities/Institutes, H1 2020

Products under Investigation by Universities/Institutes, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Abbisko Therapeutics Co Ltd, H1 2020

Pipeline by Akero Therapeutics Inc, H1 2020

Pipeline by ArQule Inc, H1 2020

Pipeline by Bayer AG, H1 2020

Pipeline by Blueprint Medicines Corp, H1 2020

Pipeline by Eddingpharm Inc, H1 2020

Pipeline by Eisai Co Ltd, H1 2020

Pipeline by Eli Lilly and Co, H1 2020

Pipeline by EUSOL Biotech Co Ltd, H1 2020

Pipeline by Everest Medicines Ltd, H1 2020

Pipeline by Genosco Inc, H1 2020

Pipeline by H3 Biomedicine Inc, H1 2020

Pipeline by ImmunoForge Co Ltd, H1 2020

Pipeline by Incyte Corp, H1 2020

Pipeline by InnoCare Pharma Ltd, H1 2020  
Pipeline by Johnson & Johnson, H1 2020  
Pipeline by NGM Biopharmaceuticals Inc, H1 2020  
Pipeline by Principia Biopharma Inc, H1 2020  
Pipeline by QED Therapeutics Inc, H1 2020  
Pipeline by Vichem Chemie Research Ltd, H1 2020  
Dormant Products, H1 2020  
Dormant Products, H1 2020 (Contd..1), H1 2020  
Discontinued Products, H1 2020



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020  
Number of Products under Development by Therapy Areas, H1 2020  
Number of Products under Development by Top 10 Indications, H1 2020  
Number of Products by Mechanism of Actions, H1 2020  
Number of Products by Stage and Mechanism of Actions, H1 2020  
Number of Products by Routes of Administration, H1 2020  
Number of Products by Stage and Routes of Administration, H1 2020  
Number of Products by Molecule Types, H1 2020  
Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

Abbisko Therapeutics Co Ltd  
Akeru Therapeutics Inc  
ArQule Inc  
Bayer AG  
Blueprint Medicines Corp  
Eddingpharm Inc  
Eisai Co Ltd  
Eli Lilly and Co  
EUSOL Biotech Co Ltd  
Everest Medicines Ltd  
Genosco Inc  
H3 Biomedicine Inc  
ImmunoForge Co Ltd  
Incyte Corp  
InnoCare Pharma Ltd  
Johnson & Johnson  
NGM Biopharmaceuticals Inc  
Principia Biopharma Inc  
QED Therapeutics Inc  
Vichem Chemie Research Ltd

## I would like to order

Product name: Fibroblast Growth Factor Receptor 4 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/F3A00A9CA682EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F3A00A9CA682EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970